BACKGROUND Transcatheter aortic valve replacement provides results comparable to those of surgery in patients at
A ortic stenosis is a major cause of cardiovascular morbidity and mortality. Many patients with severe and symptomatic aortic stenosis are successfully treated with surgical aortic valve replacement (1, 2) . For those deemed poor surgical candidates (3), mortality after 1 year with standard medical therapy may be as high as 50% (4) (5) (6) . Transcatheter aortic valve replacement (TAVR) in patients unsuitable for surgical aortic valve replacement has reduced mortality (7, 8) , and treatment of selected patients at high surgical risk has resulted in similar (balloon-expandable valve) (9) or better (self-expanding valve) (10) 1-year survival. However, there remain infrequent, specific, and significant complications with TAVR that impact long-term outcomes and may limit its use in lowerrisk patients (11, 12) . Precise valve positioning can be challenging with currently available devices, and valve misplacement can lead to severe complications, including coronary occlusion and valve embolization (13) . Incomplete apposition of the prosthesis with the native valve can occur in the presence of significant amounts of calcium or with suboptimal implantation, resulting in paravalvular regurgitation (PVR) (14, 15) . This has been associated with increased mortality in several longitudinal registries (16) (17) (18) .
The Lotus Valve System incorporates several features intended to improve upon first-generation transcatheter devices (19) . The valve is fully repositionable and retrievable and has a unique adaptive seal designed to minimize PVR. In the REPRISE I feasibility study (REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve SystEm), valve implantation resulted in minimal aortic regurgitation, with hemodynamic and clinical benefits at 1-year followup and a low rate of adverse events (20) . We describe here 30-day outcomes, the primary endpoint in the prospective, single-arm, multicenter, 120-patient REPRISE II CE-Mark study, which was designed to assess safety and performance of this novel system in patients at high risk for surgical intervention. The study is registered at ClinicalTrials.gov (unique identifier NCT01627691).
METHODS DEVICE DESCRIPTION. The Lotus Aortic Valve
Replacement System (Boston Scientific Corporation, Marlborough, Massachusetts) has been described previously (19) . Briefly, it includes a pre-attached bioprosthetic bovine pericardial aortic valve mounted within a woven nitinol wire frame and a catheter- The Lotus valve has 3 bovine pericardial tissue leaflets, a braided nitinol frame, a central radiopaque marker to aid positioning, and a polyurethane/polycarbonate outer seal designed to conform to irregular anatomic surfaces and minimize paravalvular leak. The braided structure shortens axially and expands radially during implantation and is locked in position using a post-and-buckle locking mechanism.
Meredith AM et al. (38) , and the data were compared using a 
AS, Repositionable Valves, and TAVR S E P T E M B E R 3 0 , 2 0 1 4 : 1 3 3 9 -4 8 surgical risk scores imperfectly characterize risk, the local heart teams at the centers also considered other comorbidities and patient frailty and confirmed all patients to be at high risk for surgery. were female, and 76% were NYHA functional class III or IV. The mean STS score and euroSCORE (European System for Cardiac Operative Risk Evaluation) II (39) were 7.1 AE 4.6% and 6.9 AE 5.8%, respectively.
OUTCOMES. Patient flow and procedural outcomes are shown in Figure 2 and Values are % (n/N) unless otherwise indicated. N ¼ 120 patients overall. *Data are for the last valve attempted. †In 4 patients, a 23-mm valve was inserted, but assessment before valve release indicated the valve was too small for the annulus, and the valve was fully retrieved and replaced with a 27-mm valve. In 1 patient, because of the length of the procedure and subsequent concerns about poor leaflet hydration, the investigator successfully replaced one 23-mm valve with another. In another patient, extensive handling due to difficulty crossing a heavily calcified annulus led to wire replacement and replacement of a 27-mm valve with another 27-mm valve. ‡The single death was associated with cardiac perforation and tamponade. §All patients with a mean gradient $20 mm Hg post-procedure received a 23-mm valve.
BMI ¼ body mass index; EOA ¼ effective orifice area; TAV ¼ transcatheter aortic valve. Mitral regurgitation, moderate or severe † 11.6 (13) Values are mean AE SD (n) or % (n). *2.7% were severe. †All were moderate.
CABG ¼ coronary artery bypass graft; COPD ¼ chronic obstructive pulmonary disease; euroSCORE ¼ European System for Cardiac Operative Risk Evaluation; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention; STS ¼ Society of Thoracic Surgeons.
Meredith AM et al. Table 2 ). Figure 3 shows mean aortic gradient and effective orifice area over time; changes were statistically significant from baseline to discharge and 30 days. Additional valve performance data were determined by independent core laboratory analyses of TTE outcomes (n ¼ 112 at baseline, n ¼ 110 at discharge/7 days, n ¼ 103 at 30 days) and are shown in Table 3 and Values are mean AE SD (n) or % (number/sample size). The core laboratory independently assessed the data; the number of evaluable echocardiograms for each outcome is indicated. *Significant change (p < 0.001) from baseline to 30 days (paired Student t test). †There was 1 case of severe mitral regurgitation at discharge/7 days; otherwise, all were moderate.
S E P T E M B E R
LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; mod/sev ¼ moderate/severe.
Meredith AM et al. The core laboratory independently assessed the data. The number of echocardiograms evaluable for aortic regurgitation is indicated for each time point. Post-dilation was not allowed per protocol and was not performed in any patient. All stroke ‡ 5.9 (7) Disabling stroke 1.7 (2) Nondisabling stroke 4.2 (5) All-cause mortality and disabling stroke 5.9 (7) Life-threatening/disabling bleeding 5.0 (6) Major bleeding Values are % (n). *Events were adjudicated by the clinical events committee. †One patient withdrew consent. ‡A neurologist assessed all patients before and after transcatheter aortic valve replacement. §In the 1 patient adjudicated as having a coronary obstruction, the event was related to stent thrombosis that occurred during balloon aortic valvuloplasty in a recently placed mid-left anterior descending artery stent. The valve was deployed, coronary access was intact, and the stent thrombosis was treated successfully. ¶There were 2 major vascular complications related to access site.
CHF ¼ congestive heart failure.
Meredith AM et al. Values are % (n/N) or n. *All new conduction disorders were apparent immediately post-procedure in patients in whom a newly implanted permanent pacemaker was required. †Overstretch was defined as the nominal valve area divided by the LVOT or annular area as assessed by the computed tomography core laboratory (40) . deaths, and 1 patient had withdrawn from the study. ian.meredith@myheart.id.au.
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